Insight

May 14, 2024, 16:12

Myeloma Paper of the Day, May 14th, suggester by Robert Orlowski

Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:

“Myeloma Paper of the Day: Dara-CyBorD induction shows better outcomes vs. CyBorD for transplant-ineligible myeloma patients (median PFS 25.8 vs 16.8 mos.; ORR 86% vs 65%; VGPR 52% vs 28%).

However, data look worse than even just Rd in MAIA (34.4 month PFS).”

Source: Robert Orlowski/X

Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma

Authors: Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, Edwin Lee, Kerry Taylor, Tara Cochrane, Craig Wallington-Gates, Fiona Kwok, Nicholas Weber, Ian Kerridge, Helen Weston, P. Joy Ho, Michael F Leahy, Noemi Horvath, and Andrew Spencer.

Myeloma Paper of the Day

Other insights by Robert Orlowski on OncoDaily.

AMaRC 03-16 trial Andrew Spencer Bortezomib cancer Craig Wallington-Gates Cyclophosphamide Daratumumab dexamethasone Edwin Lee Fiona Kwok Hang Quach Helen Weston Ian Kerridge John Reynolds Kerry Taylor MD Anderson Cancer Center Michael F Leahy Myeloma Paper of the Day Nicholas Weber Noemi Horvath OncoDaily Oncology P. Joy Ho Peter Mollee Philip Campbell Robert Orlowski Simon Gibbs Sophie Lee Tara Cochrane Wojt Janowski

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

Special Coverage